Protara Therapeutics, Inc. Common Stock
$3.62
-$0.13 (-3.47%)
$3.62Day Range$3.87
Key Statistics
Market Cap
$221.61M
Shares Outstanding
59.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 10, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$3.78
Day High
$3.87
Day Low
$3.62
Volume
2.06M
VWAP
$3.73
Prev Close
$3.75
Transactions
--
Acc. Volume
--
About Protara Therapeutics, Inc. Common Stock
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283651 employees345 PARK AVENUE SOUTH, NEW YORK, NY, 10010646-844-0337IPO Jan 10, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001359931
- Composite FIGI
- BBG001ZLYSH5
- Share Class FIGI
- BBG001ZLYSK1
- Ticker Root
- TARA
- SIC Code
- 2836
About Protara Therapeutics, Inc. Common Stock (TARA) Stock
Protara Therapeutics, Inc. Common Stock (TARA) closed the 2026-09-16 session at $3.62, down 3.47% versus the previous close (-0.13). The stock opened at $3.78 and traded between $3.62 and $3.87 during that session. Session trading volume was 2.1M shares. The volume-weighted average price (VWAP) is $3.73.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Protara Therapeutics, Inc. Common Stock has a market capitalization of $221.6 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. TARA is listed on the XNAS exchange. The company employs approximately 51 people. Protara Therapeutics, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2020-01-10.
On this page you can find market TARA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.